Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans)

The current International Headache Society guidelines for migraine clinical trials recommend assessment of pain relief at 2 hours as a primary end poi nt. Patients, however, express a clear preference for more rapid pain relie f, with most patients defining rapid relief as occurring within 30 minutes after drug administration. Thus, consideration should be given to establish ing clinical trial end points that more accurately reflect the preferences of patients with migraine. In this case, assessment of pain relief at 1 hou r would be an appropriate primary end point. Using speed of relief as a cri terion for migraine drug selection also is appropriate. The migraine-specif ic serotonin(1B/1D) agonists, or triptans, are able to meet this faster rel ief end point and are preferred by patients.